Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2017

Castellanos Emily, Feld Emily, Horn Leora

Abstract excerpt

EGFR-mutated NSCLC is a genetically heterogeneous disease that includes more than 200 distinct mutations. The implications of mutational subtype for both prognostic and predictive value are being increasingly understood. Although the most common EGFR mutations-exon 19 deletions or L858R mutations-predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs), it is now being recognized that outcomes may be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 28017789
DOI: 10.1016/j.jtho.2016.12.014

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.PMID 28017789Read ↗

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical ScenarioSemantic proximity Read ↗

Clinical Impact of EGFR Mutation Subtypes on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: An Austrian Real-World StudySemantic proximity Read ↗

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancerSemantic proximity Read ↗

Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report.Semantic proximity Read ↗

Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancer.Semantic proximity Read ↗

Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations.Semantic proximity Read ↗

Uncommon EGFR mutations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.Semantic proximity Read ↗

Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.Semantic proximity Read ↗

Exploring the Cause of Survival Disparities in EGFR-mutated Lung Cancer Subtypes: Unraveling Distinctive Genomic and Phenotypic Features of 19Del and L858R Mutation SubtypesSemantic proximity Read ↗

Prevalence of uncommon epidermal growth factor receptor ( EGFR ) Mutations in Non-Small Cell Lung Carcinoma (NSCLC): A tertiary cancer care center experience.Semantic proximity Read ↗

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.